ANALYSIS OF COMPLICATIONS AMONG PATIENTS AFTER PREVIOUS NEW CORONOVIRAL COVID-19 INFECTION

2021 ◽  
pp. 15-23
Author(s):  
Дмитрий Валериевич Судаков ◽  
Олег Валериевич Судаков ◽  
Артём Николаевич Шевцов ◽  
Евгений Владимирович Белов ◽  
Оксана Александровна Андросова
Keyword(s):  
Lung Tissue ◽  
Tissue Damage ◽  
Clinical Manifestations ◽  
Physical Exertion ◽  
Treatment And Prevention ◽  
Organ Systems ◽  
Coronavirus Infection ◽  
Group 2 ◽  
Almost All ◽  
Lung Tissue Damage

Статья посвящена анализу возникающих осложнений различных органов и систем органов у пациентов перенесших новую коронавирусную инфекцию. Данная тематика в настоящее время представляет большой интерес для врачей самых разнообразных специальностей. Подобный интерес обусловлен тем, что пандемия Covid-19 возникла лишь в 2020 году. Врачам и ученым, несмотря на все прилагаемые ими усилия еще не удалось полностью расшифровать природу вирусной инфекции, не удалось определить все аспекты этиологии и патогенеза. В настоящее время множество ресурсов различного плана практически во всех странах мира направлены, как на решение данных аспектов, так и на изучение основных клинических проявлений новой коронавирусной инфекции, вариантов ее лечения и предупреждения возможных осложнений, изучение которых и стало целью данной работы. Объектами исследования послужило 200 пациентов, мужчин и женщин трудоспособного возраста, перенесших Covid-19 и обращающихся в стационар и в поликлинику с различными жалобами. Все больные были разделены на 4 группы по 50 человек. 1 группу составили пациенты, которые перенесли данную инфекцию бессимптомно или в легкой форме, зачастую узнав о болезни по результатам определения антител в крови (иммуноглобулины G). 2 группу составили больные, которым был поставлен диагноз «пневмония» 1 степени (по объему поражения легочной ткани). 3 группу составили пациенты, которым был поставлен диагноз «пневмония» 2 степени (по объему поражения легочной ткани). 4 группу составили больные, которым был поставлен диагноз «пневмония» 3 степени (по объему поражения легочной ткани). Было установлено, что наиболее часто встречались осложнения дыхательной, сердечно-сосудистой и пищеварительной систем. Осложнения на нервную систему, опорно-двигательную и выделительную у данных испытуемых встречались гораздо реже. При этом по отдельным нозологиям и симптомам наиболее часто выделяли: дыхательная система - кашель и одышка при физической нагрузки (которой ранее не наблюдалось); сердечно-сосудистая система - боли в области сердца и различные нарушения ритма; пищеварительная система - симптоматика панкреатита и холецистита. Подобное исследование может быть интересным не только для врачей, занимающихся лечением пациентов с Covid-19, но и для врачей, занимающихся лечением последствий данной инфекции The article is devoted to the analysis of emerging complications of various organs and organ systems in patients who have undergone a new coronavirus infection. This topic is currently of great interest for doctors of various specialties. This interest is due to the fact that the Covid-19 pandemic only emerged in 2020. Doctors and scientists, despite all their efforts, have not yet been able to fully decipher the nature of the viral infection, have not been able to determine all aspects of the etiology and pathogenesis. Currently, many resources of various kinds in almost all countries of the world are aimed both at solving these aspects and at studying the main clinical manifestations of a new coronavirus infection, options for its treatment and prevention of possible complications, the study of which became the purpose of this work. The objects of the study were 200 patients, men and women of working age, who had undergone Covid-19 and went to a hospital and a polyclinic with various complaints. All patients were divided into 4 groups of 50 people. Group 1 consisted of patients who underwent this infection asymptomatically or in a mild form, often learning about the disease by the results of the determination of antibodies in the blood (immunoglobulins G). Group 2 consisted of patients who were diagnosed with pneumonia of the 1st degree (by the volume of lung tissue damage). Group 3 consisted of patients who were diagnosed with grade 2 pneumonia (by the volume of lung tissue damage). Group 4 consisted of patients who were diagnosed with grade 3 pneumonia (by the volume of lung tissue damage). It was found that the most common complications of the respiratory, cardiovascular and digestive systems. Complications of the nervous system, musculoskeletal and excretory systems were much less common in these subjects. At the same time, according to individual nosologies and symptoms, the following were most often distinguished: respiratory system - cough and shortness of breath during physical exertion (which was not previously observed); cardiovascular system - pain in the heart and various rhythm disturbances; digestive system - symptoms of pancreatitis and cholecystitis. Such a study may be interesting not only for doctors treating patients with Covid-19, but also for doctors treating the consequences of this infection

Clinical laboratory and radiation parameters associated with different outcomes of severe new coronavirus infection (COVID­19) with pneumonia in patients receiving tocilizumab

MedAlliance ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 35-42
Keyword(s):  
Lung Tissue ◽  
Tissue Damage ◽  
Ferritin Level ◽  
High Morbidity ◽  
Neutrophil Lymphocyte Ratio ◽  
Coronavirus Infection ◽  
Anti Inflammatory ◽  
Group 2 ◽  
Lung Tissue Damage ◽  
Group 1

ntroduction. Coronavirus infection 2019 (COVID-19) is characterized by high morbidity and mortality. Interleu- kin-6 receptor inhibitors, including tocilizumab, are used for the anti-inflammatory therapy of COVID-19. The aim of the study was to compare the clinical, lab and radia- tion characteristics of surviving and deceased patients with severe COVID-19 and pneumonia caused by SARS- CoV-2 who received tocilizumab and identify features that were associated with various outcomes. Methods. The medical records of 31 hospitalized COVID-19 pa- tients were stu died. All patients received a single dose of tocilizumab 400 mg. Two groups were created. Group 1 included 17 patients who were discharged with improve- ment, Group 2–14 fatal cases. The methods of parametric and nonparametric statistics were used for processing. Results. The condition of patients from Group 2 more often than in Group 1 was assessed as severe already at admission, p=0.022. Only 4 patients from Group 1 and all patients from Group 2 were allocated to the intensive care unit; the mechanical ventilation was used exclusively in group 2, p <0.001. The groups differed in terms of the SpO2 le vel, p=0.023, and the concentration of C-reactive protein (CRP) at admission, p=0.047, as well as in the vo- lume of lung tissue damage, p=0.027. Tocilizumab was admi nistered to all patients within a comparable period from the onset of the disease. There was an increase in the neutrophil/lymphocyte ratio in peripheral blood (NLR) by the day of its administration in Group 2, p=0.026. The NLR le vel increased even more significantly within 5–7 days after administration, p=0.045 (p=0.007 compared to baseline). The NLR value in Group 2 changed insigni- ficantly. The blood ferritin level in patients from Group 1 by the day of tocilizumab administration was lower than in Group 2, p=0.014, and decreased after the treatment, p=0.01, in contrast to Group 2. The decrease in the CRP concentration after the appointment of tocilizumab in Group 1 was also significant, p=0.001. Conclusions. The deceased COVID-19 patients who received tocilizu- mab were characterized, compared with the survivors, by the initially more severe course of the disease, more pronounced hypoxemia, as well as the volume of lung tissue damage and laboratory abnormalities, inclu ding the le vels of NLR, CRP and ferritin. Monitoring of these in- dicators appears to be necessary to assess the course of COVID-19 and make a decision on the anti-inflammatory therapy with tocilizumab.

Hematological indicators for lung damage caused by COVID-19 infection

2020 ◽  
Vol 65 (11) ◽  
pp. 676-682
Author(s):  
E. A. Borodulina ◽  
Zh. P. Vasneva ◽  
B. E. Borodulin ◽  
E. S. Vdoushkina ◽  
L. V. Povalyaeva ◽  
...  
Keyword(s):  
Clinical Manifestations ◽  
Blood Analysis ◽  
Lung Damage ◽  
Pcr Analysis ◽  
Coronavirus Infection ◽  
Ct Data ◽  
Group 2 ◽  
Hematological Indicators ◽  
Lung Tissue Damage ◽  
Damage Characteristic

During the pandemic of a new coronavirus infection one of the most serious complications is pneumonia. When entering a specialized pulmonology Department, the presence of pneumonia is confirmed by computed tomography (CT), the etiology is confirmed by the detection of SARS-CoV-2 RNA by PCR, the article analyzes the indicators of blood analysis when patients are admitted to the hospital. All admitted patients were divided into 2 groups. Group 1 of the study - with a new coronavirus infection Covid-19, confirmed by the detection of PCR-RNA SARS-CoV-2 (n=27). Group 2 consisted of 65 patients (70.7%) with lung tissue damage characteristic of Covid-19 according to CT, who had a negative analysis of PCR-RNA SARS-CoV-2. Statistically significant deviations were shown in a decrease in the percentage and absolute content of lymphocytes, monocytes and platelets, and an increase in neutrophils. The comparative analysis in the groups with positive and negative PCR analysis for the detection of SARS-CoV-2 RNA showed no statistically significant differences. It can be assumed that with the similarity of clinical manifestations and CT-data, a negative result of PCR-RNA SARS-CoV-2 can be diagnosed as «lung damage caused by COVID-19 infection».

scholarly journals 2019 Novel Coronavirus Infection in Children and Infants: Where We Are and What We Know?

2020 ◽  
Vol 15 (5) ◽  
Author(s):  
Niloofar Deravi ◽  
Shirin Yaghoobpoor ◽  
Mobina Fathi ◽  
Kimia Vakili ◽  
Elahe Ahsan ◽  
...  
Keyword(s):  
High Mortality ◽  
Current Knowledge ◽  
Clinical Manifestations ◽  
Mortality And Morbidity ◽  
Treatment And Prevention ◽  
Therapy Strategy ◽  
The World ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Almost All

: Since the outbreak of coronavirus disease 2019 (COVID-19), in Wuhan, China, there were more than 10,021,401 confirmed infected cases. This infection has spread to almost all countries around the world with reported high mortality and morbidity. Infections in children and infants have been reported as well. The condition of the infected children was mostly mild. To date, there have been reported deaths in pediatrics testing positive for COVID-19 in countries such as China, Italy and America. The therapy strategy for the children who suffer coronavirus disease (COVID-19) has been based on the adult experience. The present review summarizes current knowledge of the etiology, epidemiology, clinical manifestations, transmission, diagnosis, treatment, and prevention of COVID-19 infection in children and infants.

Methods of early diagnostics of severe pneumonia in children

2020 ◽  
Vol 03 (04) ◽  
pp. 43-46
Author(s):  
Sabir Nurgalam Amiraliev ◽  
Keyword(s):  
Young Children ◽  
Key Words ◽  
Lung Tissue ◽  
Tissue Damage ◽  
Severe Pneumonia ◽  
Early Diagnostics ◽  
Key Words Pneumonia ◽  
Pneumonia Severity ◽  
Acute Pneumonia ◽  
Lung Tissue Damage

Studies have shown that the severity and outcome of acute pneumonia largely depends on the prevalence of the focus of inflammation in the lung tissue, which is determined radiologically. We analyzed and determined a statistically significant effect of the degree of lung tissue damage on the severity and prognosis of pneumonia in young children, taking into account the conditions of infection. In pneumonia, χ² = 47.13 (p <0.001), indicates that the greater the degree of damage, the greater the likelihood of a severe course and unfavorable outcome of pneumonia. Key words: pneumonia, severity of the course, outcome, young children

scholarly journals Pengaruh Pemberian Taurin terhadap Gambaran Histopatologi Paru Mencit (Mus musculus) yang Diinduksi Karsinogen Benzo(α)Piren secara In Vivo

2017 ◽  
Vol 17 (1) ◽  
pp. 22
Author(s):  
Arini Pradita Roselyn ◽  
Endang Linirin Widiastuti ◽  
G. Nugroho Susanto ◽  
Sutyarso '
Keyword(s):  
Lung Tissue ◽  
Mus Musculus ◽  
Tissue Damage ◽  
Corn Oil ◽  
Group Vi ◽  
Normal Tissues ◽  
Randomized Design ◽  
Group I ◽  
Lung Tissue Damage

Lung cancer is a disease that causes high mortality. Drugs used to prevent and cure cancer mostly causes intoxicity to the normal tissues due to its less effectiveness. Therefore, it is necessary to find out any agent or substance which works much more effective and safe for cancer treatment. The aim of the study was to elucidate the role of taurine on the lung tissue of mice (Mus musculus) induced by carcinogenic benzo(α)pyrene. The experiment was conducted in a completely randomized design with 5 replications. Six treatment groups were perfomed. Group I was given 0.2 mL of corn oil and given aquadest until the end of the study period, group II was induced by benzo(α)pyrene without administration of taurine, group III before induced with benzo(α)pyrene, was given taurine dosage 7.8 mg/BW/day for two weeks, group IV after induced benzo(α)pyrene, was given taurine with dosage 3.9 mg/BW/day, group V after induced benzo(α)pyrene, was given taurine with dosage7. 8 mg/BW/day, group VI after induced with benzo(α)pyrene, was given taurine with dosage 15.6 mg/BW/day. The results of the Kruskal-Wallis analysis and one way ANOVA with LSD (p>0,05) showed that taurine reduced lung tissue damage 72.73% due to the administration of benzo(α)pyrene of 0.3 mg/BW/day. In addition, the effective dose of taurine reduce lung tissue damage was 15.6 mg/BW/day.

scholarly journals The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’

2021 ◽  
Vol 13 (1) ◽  
pp. 57-66
Author(s):  
V. V. Kovalchuk
Keyword(s):  
Emotional Disorders ◽  
Clinical Manifestations ◽  
Cerebrovascular Diseases ◽  
Recent Experience ◽  
Treatment And Prevention ◽  
State Recovery ◽  
Group 2 ◽  
State Examination ◽  
Group 1

COVID-19 worsens the course of cerebrovascular diseases (CVD), including chronic cerebral ischaemia (CCI). The Actovegin drug, which has long been widely used in CCI treatment, has an antioxidant and endothelium protective effect. It makes sense to study the effect of Actovegin therapy on the clinical manifestations of CCI in patients with a recent experience of COVID-19.Objective: to evaluate Actovegin efficacy in the treatment of CCI in patients with a recent experience of COVID-19.Patients and methods. The study included 440 patients (234 female; 206 male) with a recent experience of COVID-19, suffering from CCI, their average age being 67.8 years (from 54 to 85 years). All patients were broken down into two groups of 220 people (the patients in Group 1 were administrated Actovegin, the ones in Group 2 – were not). All patients were followed up for 90 days; their condition was assessed by the severity of clinical manifestations of CCI, using special scales and questionnaires.Results and discussion. After 90 days of follow-up, the frequency of complaints of cognitive impairment, sleep disorder, dizziness, fatigue, emotional disorders, and headache in Group 1 was significantly lower than in Group 2 (p<0.05). According to Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), Multidimensional Fatigue Inventory (MFI-20), and Spiegel Sleep Questionnaire (SSQ), the average indicators improved significantly more in Group 1 than in Group 2 (p<0.05). The absence of quality of life impairment and their minimal severity were observed in Group 1 in 77.9%; in Group 2 – in 33.7% (p<0.001). Statistically significant differences between the groups of patients were also observed in relation to emotional state recovery according to the Wakefield Questionnaire and the Spielberger State Trait Anxiety inventory.Conclusion. The observational study demonstrated the efficacy of Actovegin in the treatment of main clinical manifestations of CCI in patients with recent COVID-19 experience.

Sign in / Sign up

Export Citation Format

Share Document